Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Flubendazole is a widely used anthelmintic drug belonging to benzimidazole group. The molecular mechanism of action of flubendazole is based on its specific binding to tubulin, which results in disruption of microtubule structure and function, and in the interference with the microtubule-mediated transport of secretory vesicles in absorptive tissues of helminths. The microtubule-disrupting properties of benzimidazole derivatives raised recently interest in these compounds as possible anti-cancer agents. In this minireview flubendazole effects towards selected human malignant cells including myeloma, leukemia, neuroblastoma, breast cancer, colorectal cancer and melanoma are discussed along with basic data on its pharmacokinetics, metabolism and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152 · cited 2×
“In the light of fact that BCL-2 is widely expressed in human melanoma with a recognized role in melanoma chemoresistance, this discovered mebendazole’s activity is of particular interest and deserves further examination (29).”
BackgroundIn vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., & Morris, D. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00382-2 · Cited by 139
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice
Martarelli, D., Pompei, P., Baldi, C., & Mazzoni, G. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0538-0 · Cited by 101 · cited 1×
“Another benzimidazole carbamate mebendazole was found effective in a number of in vitro models including adrenocortical carcinoma cell lines (26), non-small lung cancer cells (27), cholangiocarcinoma cancer cells (in vivo activity was noted too) (28), malignant melanoma cells (29), colon cancer cells (30, 31) and gast…”
BackgroundNygren, P., & Larsson, R. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.844359 · Cited by 83
Pourgholami, M. H., Szwajcer, M., Chin, M., Liauw, W., Seef, J., Galettis, P., Morris, D. L., & Links, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1157-8 · Cited by 69
Cited by
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Metadata
- Authors
- Čáňová, K., Rozkydalová, L., & Rudolf, E.
- Venue
- Acta Medica (Hradec Kralove, Czech Republic)
- Published
- 2017
- Volume
- 60
- Issue
- 1
- Pages
- 5-11
- ISSN
- 1211-4286 (ISSN-L)
- 1805-9694
- OpenAlex
- W2605758696
- Cited by
- 44
- References
- 6
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy. https://app.cochat.ai/papers/10.14712/18059694.2017.44
- The paper
- Čáňová, K., Rozkydalová, L., & Rudolf, E. (2017). Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy. Acta Medica (Hradec Kralove, Czech Republic). https://doi.org/10.14712/18059694.2017.44
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.